VIGILVESTLibrary
← Library

REGENERON PHARMACEUTICALS, INC.

REGN
SEC CIK 872589Price charts ↗
Writing the earnings story…

Financials

Revenue+19.0% YoY
$3.61B
Sep '23Mar '24Jun '24Sep '24Mar '25Jun '25Sep '25Mar '26
Net Income-10.1% YoY
$727.2M
Sep '23Mar '24Jun '24Sep '24Mar '25Jun '25Sep '25Mar '26
EPS (diluted)-7.2% YoY
$6.75
Sep '23Mar '24Jun '24Sep '24Mar '25Jun '25Sep '25Mar '26
Gross Margin
Sep '23Mar '24Jun '24Sep '24Mar '25Jun '25Sep '25Mar '26
Quarter endingRevenueNet incomeEPS
Mar 2026$3.61B$727.2M$6.75
Sep 2025$3.75B$1.46B$13.62
Jun 2025$3.68B$1.39B$12.81
Mar 2025$3.03B$808.7M$7.27
Sep 2024$3.72B$1.34B$11.54
Jun 2024$3.55B$1.43B$12.41
Mar 2024$3.15B$722.0M$6.27
Sep 2023$3.36B$1.01B$8.89

Annual revenue

FY21FY22FY23FY24FY25

Source filings

Download the original reports from the SEC. A 10-Q is the quarterly update; a 10-K is the detailed annual report.

Glossary

Revenue
Net income
EPS
Gross margin
Net margin
Fiscal year

Hover any underlined term for its definition.